Motley Fool Wealth Management LLC Has $13.39 Million Stock Holdings in Novo Nordisk A/S (NYSE:NVO)

Motley Fool Wealth Management LLC decreased its stake in shares of Novo Nordisk A/S (NYSE:NVO) by 9.2% during the 3rd quarter, Holdings Channel reports. The institutional investor owned 112,434 shares of the company’s stock after selling 11,430 shares during the period. Motley Fool Wealth Management LLC’s holdings in Novo Nordisk A/S were worth $13,388,000 at the end of the most recent reporting period.

Other hedge funds have also recently added to or reduced their stakes in the company. Tidal Investments LLC grew its stake in shares of Novo Nordisk A/S by 13.1% during the first quarter. Tidal Investments LLC now owns 4,146 shares of the company’s stock valued at $532,000 after purchasing an additional 481 shares during the last quarter. Linden Thomas Advisory Services LLC raised its position in shares of Novo Nordisk A/S by 18.9% during the second quarter. Linden Thomas Advisory Services LLC now owns 2,263 shares of the company’s stock worth $323,000 after acquiring an additional 360 shares during the last quarter. NBC Securities Inc. lifted its stake in shares of Novo Nordisk A/S by 23.8% during the second quarter. NBC Securities Inc. now owns 10,493 shares of the company’s stock valued at $1,497,000 after acquiring an additional 2,018 shares during the period. Indiana Trust & Investment Management CO bought a new position in Novo Nordisk A/S in the second quarter valued at about $70,000. Finally, Warther Private Wealth LLC increased its position in Novo Nordisk A/S by 388.3% in the second quarter. Warther Private Wealth LLC now owns 10,528 shares of the company’s stock worth $1,503,000 after purchasing an additional 8,372 shares during the period. Institutional investors own 11.54% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts have recently issued reports on the stock. StockNews.com raised shares of Novo Nordisk A/S from a “buy” rating to a “strong-buy” rating in a research note on Friday, November 1st. BMO Capital Markets lowered their target price on shares of Novo Nordisk A/S from $160.00 to $156.00 and set an “outperform” rating for the company in a report on Thursday, October 17th. Finally, Cantor Fitzgerald reissued an “overweight” rating and issued a $160.00 price target on shares of Novo Nordisk A/S in a research note on Wednesday, November 6th. One research analyst has rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Buy” and a consensus price target of $144.50.

Novo Nordisk A/S Stock Up 0.5 %

Shares of NYSE:NVO opened at $109.16 on Wednesday. The company has a 50 day moving average price of $112.18 and a two-hundred day moving average price of $127.59. The company has a market capitalization of $489.86 billion, a PE ratio of 35.33, a PEG ratio of 1.40 and a beta of 0.40. Novo Nordisk A/S has a 52 week low of $94.73 and a 52 week high of $148.15. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.75 and a current ratio of 0.94.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.